Peplin Inc. Announces the Initiation of Phase 3 Clinical Trials for PEP005 Gel in AK on the Face and Scalp

EMERYVILLE, Calif. & BRISBANE, Australia--(BUSINESS WIRE)--Peplin, Inc. (ASX:PLI) today announced the initiation of two Phase 3 clinical trials to confirm the efficacy and safety of PEP005 (ingenol mebutate) Gel for the treatment of actinic (solar) keratoses (AK), a common pre-cancerous skin lesion, when applied to head locations, which include the face and scalp. These trials are called REGION-IIa and REGION-IIb.